Allurion Patents | Allurion Weight-Loss Balloon

Choose your country or region in order to display more relevant content.

Select

Other country or region

Country

Language

Continue

Allurion® products are protected in the US and internationally by the following patents:

US Patents, Elipse® Gastric Balloon (All versions through current):

US Patent No. 8814898

US Patent No. 8870907

US Patent No. 8974483

US Patent No. 9387107

US Patent No. 9827129

US Patent No.10182932

Other US Patents:

US Patent No. 9849018

US Patent No.10307279

US Patent No.10470908

US Patent No.10588768

US Patent No.10583024

International Patents, Elipse® Gastric Balloon (All versions through current):

Australia

AU 2013222419

AU 2014342014

AU 2017204386

China

ZL 2013 8 00104184

ZL 2014 8 0071908.X

France

EP2817062

EP3189817

Germany

DE 60 2013 013 543.6

DE 60 2013 045 422.1

Ireland

EP2817062

EP3189817

Israel

IL 234139

Italy

EP 2817062

EP 3189817

Japan

JP 6311936

Korea (Republic of)

KR 10-1872064

Mexico

MX 349195

Russia

RU 2601995

Singapore

SG 11201404821U

Spain

EP2817062

EP3189817

United Kingdom

EP2817062

EP3189817

Other International Patents:

France

EP2916904

Germany

DE 60 2013 035 222.4

Ireland

EP2916904

United Kingdom

EP2916904

*As with any medical solution, results may vary from one patient to another, and some patients may not respond to treatment. Please consult a doctor to carefully evaluate the risks and benefits before making your decision.
**The removal of the Allurion Balloon may, in very rare cases, require an endoscopic or surgical intervention. In rare cases, instead of being expelled through the digestive tract, the empty balloon may be vomited out.
***Eligibility for the placement of an Allurion Balloon will be assessed by a certified doctor after an initial consultation and a careful review of your medical history. In the case of an extended Allurion Program, your eligibility is reassessed before each placement to ensure you continue to meet the required conditions.

R. Ienca et al. The procedureless ellipse gastric balloon program: Multicenter experience in 1770 consecutive patients. Obes surg. 2020;30(9):3354-3362. Multicenter, prospective, non-randomized, open registry study conducted in patients with overweight or obesity from January 2016 to June 2019 in 19 international obesity centers participating in the study. A total of 1,770 patients with an average BMI of 34.4 ± 5.3 kg/m2 at baseline underwent treatment with the Elipse swallowable gastric balloon, with a monthly visit and a total follow-up of 4 months. 63 patients (3.6%) did not complete the program, and the balloon was removed before 4 months due to intolerance or other adverse effects.
World Health Organization – Key facts on Obesity and overweight (who.int).
European survey finds over three-quarters of adults with obesity have attempted to lose weight in the past year, but most have been unsuccessful – EASO.
This information is extracted from the instructions for use of the Allurion Gastric Balloon System. Version number CS137-02-ENG. If you have any questions regarding this document, please consult your doctor....

Chat with Ally